The Potential Utility of Bone Marrow or Umbilical Cord Blood Transplantation For the Treatment of Type I Diabetes Mellitus

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 4, 2011, Pages 455-464

  Mabed, Mohamed ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Autoimmune diseases; Insulin producing cells; Mesenchymal stem cells; Stem cells; cells

Indexed keywords

GLUCOSE; INSULIN;

AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CADAVER; CELL DESTRUCTION; CELL ISOLATION; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETIC PATIENT; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; REVIEW;

EID: 79952629843     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.002     Document Type: Review

References (132)

1. Tydén G., Reinholt F.P., Sundkvist G., et al. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996, 335:860-863.
2. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
3. Atkinson M.A., Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat Med 1999, 5:601-604.
4. Bach J.F., Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001, 19:131-161.
5. Rapoport M.J., Lazarus A.H., Jaramillo A., et al. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation. J Exp Med 1993, 177:1221-1226.
6. +-like thymocytes in the NOD mouse. Eur J Immunol 1996, 26:2989-2998.
7. Lederman M.M., Ellner J.J., Rodman H.M. Defective suppressor cell generation in juvenile-onset diabetes. J Immunol 1981, 127:2051-2055.
8. Asano M., Toda M., Sakaguchi N., et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996, 184:387-396.
9. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
10. + T cell levels in NOD mice. Proc Natl Acad Sci USA 2002, 99:12287-12292.
11. Liu J., Beller D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J Immunol 2002, 169:581-586.
12. Chatenoud L., Salomon B., Bluestone J.A. Suppressor T cells: they're back and critical for regulation of autoimmunity!. Immunol Rev 2001, 182:149-163.
13. Serreze D.V., Gaskins H.R., Leiter E.H. Defects in the differentiation and function of antigen-presenting cells in NOD/Lt mice. J Immunol 1993, 150:2534-2543.
14. Alleva D.G., Pavlovich R.P., Grant C., et al. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. Diabetes 2000, 49:1106-1115.
15. Dahlen E., Hedlund G., Dawe K. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. J Immunol 2000, 164:2444-2456.
16. Weaver D.J., Poligone B., Bui T., et al. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol 2001, 167:1461-1468.
17. Kukreja A., Cost G., Marker J., et al. Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest 2002, 109:131-140.
18. Yan G., Shi L., Penfornis A., et al. Impaired processing and presentation by MHC class II proteins in human diabetic cells. J Immunol 2003, 170:620-627.
19. Rabinovitch A., Suarez-Pinzon W.L. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998, 55:1139-1149.
20. Notkins A.L., Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001, 108:1247-1252.
21. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
22. Elliott R.B., Crossley J.R., Berryman C.C., et al. Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet 1981, 19:631-632.
23. Harrison L.C., Colman P.G., Dean B., et al. Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with azathioprine. Diabetes 1985, 34:1306-1308.
24. Silverstein J., Maclaren N., Riley W., et al. Immunosupression with azatioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988, 319:599-604.
25. Cyclosporin-induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988, 37:1574-1582. Canadian-European Randomized Control Trial Group.
26. Parving H.H., Tarnow L., Nielsen F.S., et al. Cyclosporine nephrotoxicity in type 1 diabetic patients: a 7-year follow-up study. Diabetes Care 1999, 22:478-483.
27. Raz I., Elias D., Avron A., et al. Beta-cell function in newly-onset type 1 diabetes and immunomodulation with a heat shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet 2001, 358:1749-1753.
28. Herold K.C., Hagopian W., Auger J.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
29. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
30. Saudek F., Havrdova T., Boucek P., et al. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004, 1:80-88.
31. Ludvigsson J., Faresjö M., Hjorth M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
32. Pavlakis M., Khwaja K. Pancreas and islet cell transplantation in diabetes. Curr Opin Endocrinol Diabetes Obes 2007, 14:146-150.
33. Morel P., Sutherland D.E., Almond P.S., et al. Assessment of renal function in type I diabetic patients after kidney, pancreas, or combined kidney-pancreas transplantation. Transplantation 1991, 51:1184-1189.
34. Singh R.P., Stratta R.J. Advances in immunosuppression for pancreas transplantation. Curr Opin Organ Transplant 2008, 13:79-84.
35. Matias P., Araujo M.R., Romão J.E., et al. Conversion to sirolimus in kidney-pancreas and pancreas transplantation. Transplant Proc 2008, 40:3601-3605.
36. Shapiro A.M., Lakey J.R., Ryan E.A., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230-238.
37. Ryan E.A., Lakey J.R., Paty B.W., et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51:2148-2157.
38. Burt R.K., Slavin S., Burns W.H., et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood 2002, 99:768-784.
39. Burt R.K., Traynor A., Statkute L., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematous. JAMA 2006, 295:527-535.
40. Voltarelli J.C., Couri C.E., Stracieri A.B., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297:1568-1576.
41. Ross L.F., Philipson L.H. Ethics in hematopoietic stem cell transplantation in type 1 diabetes mellitus (letter). JAMA 2007, 298:285.
42. Skyler J.S. Cellular therapy for type 1 diabetes: has the time come?. JAMA 2007, 297:1599-1600.
43. Couri C.E., Oliveira M.C., Stracieri A.B., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301:1573-1579.
44. Shizuru J. The experimental basis for hematopoietic cell transplantation for autoimmune diseases. Thomas' Hematopoietic Cell Transplantation 2004, 324-343. Blackwell, Malden, MA. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).
45. Sykes M., Nikolic B. Treatment of severe autoimmune disease by stem cell transplantation. Nature 2005, 435:620-627.
46. Koevary S., Rossini A., Stoller W., et al. Passive transfer of diabetes in the BB/W rat. Science 1983, 220:727-728.
47. Naji A., Silvers W.K., Barker C.F. Autoimmunity and type I (insulin-dependent) diabetes mellitus. Transplantation 1983, 36:355-361.
48. Ikehara S., Ohtsuki H., Good R.A., et al. Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation. Proc Natl Acad Sci USA 1985, 82:7743-7747.
49. Vialettes B., Maraninchi D., San Marco M.P., et al. Autoimmune polyendocrine failure type 1 (insulin-dependent) diabetes mellitus and hypothyroidism after allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia. Diabetologia 1993, 36:541-546.
50. Nelson J.L., Torrez R., Louie F.M., et al. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl 1997, 48:23-29.
51. Hinterberger W., Hinterberger-Fischer M., Marmont A. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 2002, 30:753-759.
52. Schranz D.B., Lenmark A. Immunology in diabetes: an update. Diabetes Metab Rev 1998, 14:3-29.
53. Yasumizu R., Sugiura K., Iwai H., et al. Treatment of type 1 diabetes mellitus in non-obese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue. Proc Natl Acad Sci USA 1987, 84:6555-6557.
54. Itakura S., Asari S., Rawson J., et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant 2007, 7:336-346.
55. Barrett A.J., Rezvani K., Solomon S., et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program 2003, 1:350-371.
56. Imamura M., Tsutsumi Y., Miura Y., et al. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 2003, 8:19-26.
57. Girman P., Kriz J., Dovolilova E., et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. Ann Transplant 2001, 6:43-45.
58. Alexander S.I., Smith N., Hu M., et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008, 358:369-374.
59. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance imunosuppression. N Engl J Med 2008, 358:353-361.
60. Scandling J.D., Busque S., Dejbakhsh-Jones S., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008, 358:362-368.
61. Maraninchi D., Gluckman E., Blaise D., et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987, 2:175-178.
62. Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990, 4:687-698.
63. Colson Y.L., Shinde Patil V.R., Ildstad S.T. Facilitating cells: novel promoters of stem cell alloengraftment and donor-specific transplantation tolerance in the absence of GVHD. Crit Rev Oncol Hematol 2007, 61:26-43.
64. Jacquet E.G., Schanie C.L., Fugier-Vivier I., et al. Facilitating cells as a venue to establish mixed chimerism and tolerance. Pediatr Transplant 2003, 7:348-357.
65. Suzuki A., Nakauchi H., Taniguchi H. Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proc Natl Acad Sci USA 2003, 100:5034-5039.
66. Kojima H., Fujimiya M., Matsumura K., et al. Extrapancreatic insulin-producing cells in multiple organs in diabetes. Proc Natl Acad Sci USA 2004, 101:2458-2463.
67. Zalzman M., Gupta S., Giri R., et al. Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc Natl Acad Sci USA 2003, 100:7253-7258.
68. Tang D.Q., Cao L.Z., Burkhardt B.R., et al. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 2004, 53:1721-1732.
69. Oh S.H., Muzzonigro T.M., Bae S.H., et al. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. Lab Invest 2004, 84:607-617.
70. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
71. Beilhack G.F., Scheffold Y.C., Weissman I.L., et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 2003, 52:59-68.
72. Choi J.B., Uchino H., Azuma K., et al. Little evidence of transdifferentiation of bone marrow-derived cells into pancreatic beta cells. Diabetologia 2003, 46:1366-1374.
73. Lechner A., Yang Y.G., Blacken R.A., et al. No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. Diabetes 2004, 53:616-623.
74. Ianus A., Holz G.G., Theise N.D., et al. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest 2003, 111:843-850.
75. Hess D., Li L., Martin M., et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 2003, 21:763-770.
76. Hussain M.A., Theise N.D. Stem-cell therapy for diabetes mellitus. Lancet 2004, 364:203-205.
77. Couri C.E.B., Foss M.C., Voltarelli J.C. Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting beta-cell regeneration. Braz J Med Biol Res 2006, 39:1271-1280.
78. Lu D., Mahmood A., Wang L., et al. Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outcome. Neuroreport 2001, 12:559-563.
79. Chamberlain G., Fox J., Ashton B., et al. Concise review. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007, 25:2739-2749.
80. Chapel A., Bertho J.M., Bensidhoum M., et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003, 5:1028-1038.
81. Bensidhoum M., Gobin S., Chapel A., et al. Therapeutic effect of human mesenchymal stem cells in skin after radiation damage. J Soc Biol 2005, 199:337-341.
82. Herrera M.B., Bussolati B., Bruno S., et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004, 14:1035-1041.
83. Cho K.A., Ju S.Y., Cho S.J., et al. Mesenchymal stem cells showed the highest potential for the regeneration of injured liver tissue compared with other subpopulations of the bone marrow. Cell Biol Int 2009, 33:772-777.
84. Chen J., Li Y., Wang L., et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001, 32:1005-1011.
85. Mahmood A., Lu D., Lu M., et al. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 2003, 53:697-702.
86. Wu G.D., Nolta J.A., Jin Y.S., et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003, 75:679-685.
87. Orlic D., Kajstura J., Chimenti S., et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705.
88. Orlic D., Kajstura J., Chimenti S., et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001, 98:10344-10349.
89. Jackson K.A., Majka S.M., Wang H., et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001, 107:1395-1402.
90. Hofstetter C.P., Schwarz E.J., Hess D., et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA 2002, 99:2199-2204.
91. Kopen G.C., Prockop D.J., Phinney D.G. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 1999, 96:10711-10716.
92. Agung M., Ochi M., Yanada S., et al. Mobilization of bone marrow-derived mesenchymal stem cells into the injured tissues after intra-articular injection and their contribution to tissue regeneration. Knee Surg Sports Traumatol Arthrosc 2006, 14:1307-1314.
93. Vija L., Farge D., Gautier J.F., et al. Mesenchymal stem cells: stem cell therapy perspectives for type 1 diabetes. Diabetes Metab 2009, 35:85-93.
94. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
95. Le Blanc K., Tammik L., Sundberg B., et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
96. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
97. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
98. Tse W.T., Pendleton J.D., Beyer W.M., et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
99. Ishida T., Inaba M., Hisha H., et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation: complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 1994, 152:3119-3127.
100. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
101. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third-party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
102. Ringdén O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
103. Tyndall A., Walker U.A., Cope A., et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 2007, 9:301-331.
104. Deng W., Han Q., Liao L., et al. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 2005, 24:458-463.
105. Corcione A., Benvenuto F., Ferretti E., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
106. Poggi A., Prevosto C., Massaro A.M., et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 2005, 175:6352-6360.
107. Spaggiari G.M., Capobianco A., Abdelrazik H., et al. Mesenchymal stem cells inhibit natural killer cell proliferation, cytotoxicity and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
108. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
109. Ryan J.M., Barry F.P., Murphy J.M., et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005, 2:8-19.
110. +-derived and monocyte-derived dendritic cells. J Immunol 2006, 177:2080-2087.
111. Abdi R., Fiorina P., Adra C.N., et al. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008, 57:1759-1767.
112. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
113. Xie Q.P., Huang H., Xu B., et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation 2009, 77:483-491.
114. Sun Y., Chen L., Hou X.G., et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J (Engl) 2007, 120:771-776.
115. Dong Q.Y., Chen L., Gao G.Q., et al. Allogeneic diabetic mesenchymal stem cells transplantation in streptozotocin-induced diabetic rat. Clin Invest Med 2008, 31:E328-E337.
116. Chen L.B., Jiang X.B., Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World J Gastroenterol 2004, 10:3016-3020.
117. Lee R.H., Seo M.J., Reger R.L., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 2006, 103:17438-17443.
118. Hardikar A.A. Generating new pancreas from old. Trends Endocrinol Metab 2004, 15:198-203.
119. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
120. Horwitz E.M., Gordon P.L., Koo W.K., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002, 99:8932-8937.
121. Zhang X., Li J.Y., Cao K., et al. Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases. Int J Lab Hematol 2010, 32:256-264.
122. Koç O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
123. Lazarus H.M., Koç O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
124. Fruchtman S. Stem cell transplantation. Mt Sinai J Med 2003, 70:166-170.
125. Han P., Hodge G., Story C., et al. Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br J Haematol 1995, 89:733-740.
126. Harris D.T., Badowski M., Ahmad N., et al. The potential of cord blood stem cells for use in regenerative medicine. Expert Opin Biol Ther 2007, 7:1311-1322.
127. Denner L., Bodenburg Y., Zhao J.G., et al. Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin. Cell Prolif 2007, 40:367-380.
128. Pessina A., Eletti B., Croera C., et al. Pancreas developing markers expressed on human mononucleated umbilical cord blood cells. Biochem Biophys Res Commun 2004, 323:315-322.
129. Yoshida S., Ishikawa F., Kawano N., et al. Human cord blood-derived cells generate insulin-producing cells in vivo. Stem Cells 2005, 23:1409-1416.
130. Ende N., Chen R., Reddi A.S. Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochem Biophys Res Commun 2004, 325:665-669.
131. Haller M.J., Viener H.L., Wasserfall C., et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 2008, 36:710-715.
132. Haller M.J., Wasserfall C.H., McGrail K.M., et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009, 32:2041-2046.